---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-22-001844"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:34:13.029192+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals appoints Seth Van Voorhees as CFO and Treasurer, effective June 13, 2022

## Summary
- Van Voorhees most recently CFO of PDS Biotechnology; prior CFO at Research Frontiers and American Pacific.
- Employment agreement: $400k annual base salary, $200k target bonus, and option grant for 325,000 shares with two-year vesting.
- Severance: nine months' salary plus prorated bonus and accelerated vesting on termination without cause or change of control.
- Company focusing resources on psychiatry franchise, particularly NRX-101 for bipolar depression with suicidality.

## SEC filing metadata
- accession: 0000950142-22-001844
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000095014222001844/0000950142-22-001844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000095014222001844/eh220259882_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-22-001844
- JSON: https://secwatch.observer/filing/0000950142-22-001844.json
- Plain text: https://secwatch.observer/filing/0000950142-22-001844.txt

## Key facts
- Executive change
  Dr. Seth Van Voorhees was appointed as Chief Financial Officer and Treasurer at NRX Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Treasurer
  source text: On June 6, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Seth Van Voorhees, 61, to serve as Chief Financial Officer (“CFO”) and Treasurer of the Company, effective June 13, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000095014222001844/0000950142-22-001844-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.